MIMEDX GROUP, INC.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
MDXG$3.37+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows – For the years ended
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities: | |||
| Net income from continuing operations | $48,578 | $41,998 | $67,439 |
| Adjustments to reconcile net income from continuing operations to net cash flows provided by operating activities from continuing operations: | |||
| Share-based compensation | 16,396 | 16,933 | 16,959 |
| Depreciation and amortization | 14,881 | 6,041 | 3,427 |
| Deferred income taxes | 8,710 | 12,472 | (37,802) |
| Credit loss expense | 6,515 | 595 | 1,449 |
| Non-cash lease expenses | 1,262 | 1,310 | 1,268 |
| Shares received in settlement of litigation | — | (9,300) | — |
| Loss on extinguishment of debt | — | 1,401 | — |
| Other | 641 | 1,112 | 613 |
| Increase (decrease) in cash resulting from changes in: | |||
| Accounts receivable | (26,394) | (2,552) | (12,237) |
| Inventory | (1,533) | (2,357) | (7,838) |
| Other assets | (8,818) | (352) | 1,252 |
| Accounts payable | 2,119 | (1,410) | 783 |
| Accrued compensation | 8,986 | 2,896 | 1,829 |
| Accrued expenses | 2,371 | (789) | (1,708) |
| Other liabilities | 289 | (870) | (497) |
| Net cash flows from operating activities of continuing operations | 74,003 | 67,128 | 34,937 |
| Net cash flows used in operating activities of discontinued operations | — | (930) | (8,162) |
| Net cash flows provided by operating activities | 74,003 | 66,198 | 26,775 |
| Cash flows from investing activities: | |||
| Cash paid for acquisitions | (3,764) | (7,862) | — |
| Purchases of equipment | (1,033) | (1,683) | (1,987) |
| Other investments | (2,089) | (38) | (168) |
| Net cash flows used in investing activities | (6,886) | (9,583) | (2,155) |
| Cash flows from financing activities: | |||
| Stock repurchased for tax withholdings on vesting of restricted stock | (3,118) | (2,641) | — |
| Cash paid for Profit Share Payment (Note 14) | (1,294) | (80) | — |
| Proceeds from Citizens Revolving Credit Facility | — | 30,000 | — |
| Proceeds from Citizens Term Loan | — | 19,783 | — |
| Prepayment premium on previous term loan | — | (500) | — |
| Deferred financing cost | — | (1,101) | — |
| Repayment of previous term loan | — | (50,000) | — |
| Repayment of Citizens Revolving Credit Facility | — | (30,000) | — |
| Principal payments on Citizens Term Loan Facility | (1,000) | (1,000) | — |
| Proceeds from exercise of stock options | — | 1,397 | 997 |
| Repurchase of Series B Preferred Shares | — | — | (9,515) |
| Other | — | (57) | (52) |
| Net cash flows used in financing activities | (5,412) | (34,199) | (8,570) |
| Net change in cash | 61,705 | 22,416 | 16,050 |
| Cash and cash equivalents, beginning of period | 104,416 | 82,000 | 65,950 |
| Cash and cash equivalents, end of period | $166,121 | $104,416 | $82,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.